Single arm phase II study of covalent #KRAS G12C inhibitor glecirasib (JAB-21822) in pts with NSCLC presented by Dr. Yuankai Shi at April #ASCOPlenarySeries . Glecirasib 800mg qday in 199pts had confirmed RR 47.9% and disease control rate of 86.3%

Now 4 out of 10 ✅

Dr. Nancy Lin (Nancy Lin, MD) discussed advances in medical treatment in today's #ESMObreast24 educational session on the management of #BrainMetastases from early detection to local and systemic treatments.
#BreastCancerBrainMetastasis #BCBM #LMD
cattendee.abstractsonline.com/meeting/20743/…

A momentous announcement from ASCO ASCOPres-Elect #EricSmall — the newly established Conquer Cancer, the ASCO Foundation Felix Feng Young Investigator Award. Standing ovation in the room.

Donate to the new #FelixFengYIA here:
p2p.conquer.org/uniteandconque…

Great recap of the randomized trials in the 2L+ HR+ MBC setting by Eva M Ciruelos. #ESMOBreast24 #ESMOAmbassadors ESMO - Eur. Oncology

Genes that should be included in germline testing panels by tumor type (including prostate cancer): ASCO guideline just published.

ascopubs.org/doi/pdf/10.120…

Neoadjuvant chemo/nivo with adjuvant nivo show ⬆️ DFS (HR 0.58) & ⬆️pCR in NSCLC. 23% & 35% didn’t have surgery/adjuvant nivo respectively. Debate about activity of neoadjuvant vs adjuvant vs both is ongoing. No OS. Similar Bladder cancer trials (durva/nivo/pembro) awaited.

🔬 Investigating the role of base excision repair factors in head and neck cancer: Implications for tumor immunogenicity and potential targets for immunotherapy. Read the full study to learn more:
journals.sagepub.com/doi/full/10.11…

#HNSCC #ImmuneResponse

📑Case study by Assoc. Ed. Sara Hurvitz Samer Alkassis, MD & team highlights the importance of monitoring kidney function during #pembrolizumab treatment in breast cancer. Timely intervention with #corticosteroids can lead to resolution of acute kidney injury

journals.sagepub.com/doi/full/10.11…

Professor Harbeck opens #ESMOBreast24 with a lecture on making personalized medicine a reality for patients facing early #bcsm .

The time has come!

ESMO - Eur. Oncology
#ESMOAmbassadors

Very intriguing talk by Nadia Harbeck on therapy adaptation and personalized medicine in early Breast cancer at the #ESMOBreast24 in Berlin. ESMO - Eur. Oncology OncoAlert Omar Abdihamid Oncologist @Garissa Cancer Center

Terrific presentation by Sara Tolaney at #ESMOBreast24 , recapitulating 10+ years of de-escalation trials and novel frontiers for the tailoring of treatment in early-stage breast cancer, including promising biomarkers such as HER2DX, PET response and MRD. #ESMOAmbassadors #bcsm

📊 Investigate #olaparib exposure and adverse effects management with this PK/PD study. Real-world data suggests a target plasma concentration for minimizing #anaemia risk. #Olaparib #CancerResearch Audrey Bellesoeur Fumet Jean-David, MD, PhD

journals.sagepub.com/doi/full/10.11…

🧪 Learn about adjuvant therapy choices in metastatic #colorectalcancer patients. Research from Taiwan Cancer Registry highlights improved survival with chemotherapy plus targeted agents, especially for certain subgroups #AdjuvantTherapy

journals.sagepub.com/doi/full/10.11…